TY - JOUR
T1 - 18F-FDG PET or PET/CT for detecting extrahepatic metastases or recurrent hepatocellular carcinoma
T2 - A systematic review and meta-analysis
AU - Lin, Chun Yi
AU - Chen, Jin Hua
AU - Liang, Ji An
AU - Lin, Cheng Chieh
AU - Jeng, Long Bin
AU - Kao, Chia Hung
N1 - Funding Information:
The grant supported by the study projects (DMR-98-052 and DMR-98-087) of our hospital and Taiwan Department of Health Clinical Trial and Research Center for Excellence ( DOH100-TD-B-111-004 ) and Taiwan Department of Health Cancer Research Center for Excellence ( DOH100-TD-C-111-005 ).
PY - 2012/9
Y1 - 2012/9
N2 - Aim: Positron emission tomography (PET) using F18-flurodeoxy-glucose (FDG) has been widely used for reflecting cellular metabolism. However, the feasibility of FDG PET in the diagnosis of hepatocellular carcinoma (HCC) is limited. The aim of the study was to assess the ability of FDG PET (PET/CT) in the detection of extrahepatic metastases or recurrent HCC. Materials and methods: We conducted MEDLINE, EMBASE and COCHRANE searches (last update, April 2011). Eight eligible articles were identified evaluating F18-FDG PET (PET/CT) in extrahepatic metastases or recurrent HCC. Two authors independently evaluated the methodological quality of each study. We estimated pooled sensitivities, specificities, summary receiver-operating-characteristic (SROC) curves, and summary likelihood ratios. Results: Eight eligible studies were enrolled in this study. The pooled estimates of sensitivity, specificity, positive likelihood ratio, and negative likelihood ratio of FDG PET (PET/CT) in the detection of metastatic HCC were 76.6%, 98.0%, 14.68, and 0.28, respectively. The pooled estimates of sensitivity, specificity, LR+ and LR- of FDG PET (PET/CT) in the detection of recurrent HCC were 81.7%, 88.9%, 4.72, and 0.19, respectively. Conclusion: Based on the results of this systematic review, F-18 FDG PET (PET/CT) was useful in ruling in extrahepatic metastases of HCC and valuable for ruling out the recurrent HCC.
AB - Aim: Positron emission tomography (PET) using F18-flurodeoxy-glucose (FDG) has been widely used for reflecting cellular metabolism. However, the feasibility of FDG PET in the diagnosis of hepatocellular carcinoma (HCC) is limited. The aim of the study was to assess the ability of FDG PET (PET/CT) in the detection of extrahepatic metastases or recurrent HCC. Materials and methods: We conducted MEDLINE, EMBASE and COCHRANE searches (last update, April 2011). Eight eligible articles were identified evaluating F18-FDG PET (PET/CT) in extrahepatic metastases or recurrent HCC. Two authors independently evaluated the methodological quality of each study. We estimated pooled sensitivities, specificities, summary receiver-operating-characteristic (SROC) curves, and summary likelihood ratios. Results: Eight eligible studies were enrolled in this study. The pooled estimates of sensitivity, specificity, positive likelihood ratio, and negative likelihood ratio of FDG PET (PET/CT) in the detection of metastatic HCC were 76.6%, 98.0%, 14.68, and 0.28, respectively. The pooled estimates of sensitivity, specificity, LR+ and LR- of FDG PET (PET/CT) in the detection of recurrent HCC were 81.7%, 88.9%, 4.72, and 0.19, respectively. Conclusion: Based on the results of this systematic review, F-18 FDG PET (PET/CT) was useful in ruling in extrahepatic metastases of HCC and valuable for ruling out the recurrent HCC.
KW - FDG PET
KW - Meta-analysis
KW - Metastatic HCC
KW - Recurrent HCC
KW - Systematic review
UR - http://www.scopus.com/inward/record.url?scp=84864695666&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84864695666&partnerID=8YFLogxK
U2 - 10.1016/j.ejrad.2011.08.004
DO - 10.1016/j.ejrad.2011.08.004
M3 - Review article
C2 - 21899970
AN - SCOPUS:84864695666
SN - 0720-048X
VL - 81
SP - 2417
EP - 2422
JO - European Journal of Radiology
JF - European Journal of Radiology
IS - 9
ER -